Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.

Cui Y, Brosnan JA, Blackford AL, Sur S, Hruban RH, Kinzler KW, Vogelstein B, Maitra A, Diaz LA Jr, Iacobuzio-Donahue CA, Eshleman JR.

Clin Cancer Res. 2012 Dec 1;18(23):6519-30. doi: 10.1158/1078-0432.CCR-12-0827. Epub 2012 Jul 2.

2.

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S.

Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.

PMID:
23470568
3.
4.

Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.

Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH, Liao JD.

Clin Cancer Res. 2005 Aug 15;11(16):6075-86.

6.

Genomic sequencing of key genes in mouse pancreatic cancer cells.

Wang Y, Zhang Y, Yang J, Ni X, Liu S, Li Z, Hodges SE, Fisher WE, Brunicardi FC, Gibbs RA, Gingras MC, Li M.

Curr Mol Med. 2012 Mar;12(3):331-41.

7.

The Arf/p53 protein module, which induces apoptosis, down-regulates histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs.

Atsumi Y, Inase A, Osawa T, Sugihara E, Sakasai R, Fujimori H, Teraoka H, Saya H, Kanno M, Tashiro F, Nakagama H, Masutani M, Yoshioka K.

J Biol Chem. 2013 May 10;288(19):13269-77. doi: 10.1074/jbc.M112.402560. Epub 2013 Mar 27.

8.

Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer.

Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, Giese NA, Friess H, Kleeff J.

Br J Cancer. 2008 Sep 2;99(5):760-7. doi: 10.1038/sj.bjc.6604528.

9.

c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.

Biliran H Jr, Banerjee S, Thakur A, Sarkar FH, Bollig A, Ahmed F, Wu J, Sun Y, Liao JD.

Clin Cancer Res. 2007 May 1;13(9):2811-21.

10.

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.

Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, Wang F, Reindl KM, Wu E, Ma Q.

BMC Cancer. 2014 Sep 20;14:686. doi: 10.1186/1471-2407-14-686.

11.

Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.

May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER, Reynolds CP.

PLoS One. 2013 Dec 2;8(12):e80060. doi: 10.1371/journal.pone.0080060. eCollection 2013.

12.

[Genetic aspects of pancreatic cancer].

Grigor'eva IN, Efimova OV, Suvorova TS, Tov NL.

Eksp Klin Gastroenterol. 2014;(10):70-6. Review. Russian.

PMID:
25911935
13.

5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.

Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos JP, Costello E.

J Gene Med. 2004 May;6(5):514-25.

PMID:
15133762
14.

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE.

Clin Cancer Res. 2005 Oct 15;11(20):7508-15.

15.

CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells.

Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R.

Cancer Res. 2011 Mar 1;71(5):1825-35. doi: 10.1158/0008-5472.CAN-10-2736. Epub 2011 Feb 22.

16.

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ.

Clin Cancer Res. 2013 Jan 1;19(1):291-303. doi: 10.1158/1078-0432.CCR-12-1611. Epub 2012 Nov 7.

17.

Effects of hypoxia on human cancer cell line chemosensitivity.

Strese S, Fryknäs M, Larsson R, Gullbo J.

BMC Cancer. 2013 Jul 5;13:331. doi: 10.1186/1471-2407-13-331.

18.

[In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].

Kreil A, Bauer J, Scheithauer W.

Acta Med Austriaca. 1999;26(3):93-100. German.

PMID:
10520377
19.

Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.

Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S.

Pancreas. 2004 Oct;29(3):193-203.

PMID:
15367885
20.

Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.

Peng B, Fleming JB, Breslin T, Grau AM, Fojioka S, Abbruzzese JL, Evans DB, Ayers D, Wathen K, Wu T, Robertson KD, Chiao PJ.

Clin Cancer Res. 2002 Nov;8(11):3628-38.

Supplemental Content

Support Center